Hit by tri­al set­back, Aslan slash­es staff and a study — hun­ker­ing down in wait for piv­otal da­ta

Two weeks af­ter re­port­ing the fail­ure of a key Phase II study of their lead drug, Aslan Phar­ma­ceu­ti­cals $ASLN is re­struc­tur­ing, slash­ing staff and shut­ter­ing a tri­al as they aim for a piv­otal win.

Out the ex­it goes Bertil Lind­mark, the chief med­ical of­fi­cer, now head­ed back to Eu­rope. The CMO is leav­ing with 30% of the staff as the biotech slash­es its burn rate in half. In oth­er staff moves Chih-Yi Hsieh, the VP Med­ical and GM Tai­wan, will take the role of act­ing CMO while COO Mark McHale be­comes head of R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER